ABVC BIOPHARMA, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ABVC BIOPHARMA, INC. on May 27, 2022. The report addresses a significant corporate governance event occurring on the same date.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific corporate event and does not contain financial statements.
Material Changes
The material change reported is the departure of a director due to death. On May 27, 2022, the company was informed that Dr. Shin-Yu Miao, a member of the Board of Directors, passed away.
Outlook and Management Commentary
Management stated that Dr. Miao was a meaningful part of the board. The remaining directors are currently seeking a suitable candidate to fill the vacancy. The company intends to file an amendment to this report once a new director is found and appointed. No other risks, contingencies, or unusual items were disclosed in this filing.
Key Facts for Investor Verification
- Dr. Shin-Yu Miao, a director of ABVC BIOPHARMA, INC., passed away on May 27, 2022.
- The Board of Directors has a vacancy and is actively searching for a replacement.
- An amendment to this 8-K will be filed upon the appointment of a new director.
- This filing contains no financial performance data.